- Trial Phase
- Phase 1/2 (Phase 2 pancreatic ductal adenocarcinoma trial enrolling)
- Time to Market
- Unknown — years away if successful. Program is in Phase 1/2; a Phase 2 pancreatic trial only began enrolling (first patient April 2026) and no registrational (Phase 3) trial has started. No FDA action or PDUFA exists on record.
- Why 4/10
- No hard, dated binary catalyst (PDUFA, pivotal/registrational readout, or FDA decision) is scheduled for nuzefatide pevedotin in the next ~12 months — the next events are undated data presentations from the enrolling Phase 2 pancreatic trial and ongoing Phase 1/2 urothelial work — so the score stays in the 3-5 mid-stage band even though the drug is one of Bicycle's two lead programs (default 4; no dated catalyst to push higher).
BCYC trades near its 52-week low (~$3.86, 52-wk range low $3.80) with a buy-heavy analyst consensus (mean price target $9.86 vs $3.86, ~185% implied upside in the local snapshot) and ~$510M cash through 2030 — but the stock is a binary, event-driven clinical story, not a value play. Watch for nuzefatide Phase 2 pancreatic-cancer data and further combo (nivolumab) urothelial data at upcoming medical meetings, and any partnership move for the sister program zelenectide pevedotin (BT8009, Duravelo-2); a Phase 2 failure in PDAC, a notoriously hard indication, would hit a small-cap trading near its low hard.
Price Chart
Executive Summary
Nuzefatide pevedotin is Bicycle Therapeutics plc's (BCYC, Nasdaq) EphA2-targeted Bicycle Toxin Conjugate and one of two lead programs (the other is zelenectide pevedotin, a separate molecule in the Duravelo trials). April 2026 Phase 1/2 data showed a 40% confirmed response rate with nivolumab in EphA2+ metastatic urothelial cancer, and a Phase 2 pancreatic cancer trial is now enrolling. BCYC is a pre-revenue clinical-stage company: Q2 2026 net loss was $50.3M (-$0.72/sh), cash was $510.1M with runway into 2030 after a March 2026 restructuring (30% workforce cut, Duravelo-3/4 deprioritized, Genentech/Novartis collaborations terminated). The stock is near its 52-week low with no FDA/PDUFA catalysts on record and no dated near-term pivotal readout, so the near-term share-price driver for THIS drug is modest — but it carries the weight of a major program at a ~$270M-market-cap company.
How It Works
A targeted cancer drug from Bicycle's "bicycle" platform: a small synthetic peptide ring (a bicyclic peptide) engineered to bind EphA2, a protein found on many solid tumors, carrying a cell-killing chemotherapy toxin (the "-pevedotin" suffix denotes an auristatin-type payload). It acts like a guided missile — docking on EphA2-positive tumor cells and delivering the toxin inside, aiming to spare healthy tissue compared with untargeted chemo. It is being tested alone-with-immunotherapy (nivolumab, a PD-1 checkpoint inhibitor) in bladder/urothelial cancer and as a single agent in pancreatic cancer.
Trial Status
Positive Phase 1/2 data announced April 2026 for nuzefatide pevedotin + nivolumab in metastatic urothelial cancer: 40% confirmed overall response rate in EphA2+ tumors, plus human imaging data supporting EphA2 as a target. First patient dosed in the Phase 2 recurrent pancreatic cancer trial April 2026; that trial is actively enrolling as of the Q2 2026 earnings update (July 30, 2026).
The Two-Sided Case
Upcoming Catalysts
- Further nuzefatide pevedotin clinical data presentations at upcoming medical meetings (undated; company cited AACR/ASCO 2026 as recent venues)
- Phase 2 pancreatic ductal adenocarcinoma trial enrollment progress and eventual initial efficacy readout (no public date; first patient dosed April 2026)
- Updated combination (nivolumab) urothelial cancer data as the Phase 1/2 cohort matures
- Any partnership/out-licensing news for zelenectide pevedotin (sister program) that would reset sentiment for the company (Duravelo-2 further data flagged for 2H 2026)
- Quarterly earnings updates (next 10-Q/8-K) tracking cash burn against the 'runway into 2030' claim
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BICYCLE THERAPEUTICS PLC 8-K BCYC ·Originating report